--91. (New) The method according to claim 87, which comprises controlling the average cooling rate of the solution in the temperature range of from (heating temperature in (C2)) to (said heating temperature -30°C) to not less than 30°C/hour and not more than 90°C/hour in (D2).--

Ex Cost

--92. (New) The method according to claim 87, which comprises controlling the average cooling rate of the solution in the temperature range of from (heating temperature in (C2)) to (said heating temperature -30°C) to not less than 1°C/hour and less than 30°C/hour in (D2).--

REMARKS

Applicants request entry of the foregoing amendments, and consideration of new claims 62-93. After entry of this amendment, claims 1, 4-10, 12, 13, 16-33, 36-59 and 61-92 are pending.

This amendment is entered to introduce claims which are potentially subject to an interference with U.S. Patent Application Serial No. 09/824,447, filed April 2, 2001, which was published December 6, 2001 as U.S. Patent Application Publication No. 2001/0049450 A1. The '450 publication was made of record in this application in the Information Disclosure Statement filed October 17, 2002.

Support for new claims 62-92 is found in the application as originally filed, as described below.

Serial No. 09/730,380 Response Under 37 C.F.R. §1.111 Docket No. 5432/01004 Page 7

Citalopram Salt Crystal Claims

New claims 62-76 cover citalopram salt crystals.

Support for claims 62 and 65 is found in the application as filed, at Example 1 (page 9) and Table 1 (page 10). Support for claims 63 and 66 is found in the application as filed, at Example 2 (page 9) and Table 1 (page 10). Support for claims 64 and 67 is found in the application as filed, at Example 3 (page 9) and Table 1 (page 10). Support for claim 68 is found in the application as filed, at page 4, lines 17-18 and in original claims 16 to 18.

New crystal claims 69-76 are copied from the pending claims of Application Serial no. 09/824,447, as follows:

Corresponding Claim in Application Serial No. 09/824,447
1
2
3
4
5
6
7
8

Serial No. 09/730,380 Response Under 37 C.F.R. §1.111 Docket No. 5432/01004

Page 8

Support for claims 69-76 is found in the application as filed, including at

Examples 1-3, Table 1, at page 4, lines 17-18, page 5, lines 28-31, page 7, lines 17-19, and in the

description of the method of crystallization of the invention.

Method of Crystallization Claims

New claims 77-92 cover methods of crystallizing citalopram hydrobromide.

Support for claim 77 is found in original claim 20, and in the application as filed, at page 4, lines

20-27, and page 7, line 24 to page 8, line 16.

Support for the range of 20°C to 40°C in claim 78 and the range of 25°C to 35°C

in claim 79 is found in the application as filed, at page 8, lines 4-6. Support for the average

cooling rate of 20°C in claim 80 is found in the application as filed at Examples 1 (page 8, lines

7-8) and 2 (page 9, lines 16-18), and at page 8, lines 9-14.

Support for the addition of a seed crystal in claim 81 is found in the application as

filed, at page 4, lines 20-27 and at page 8, lines 4-9.

New claims 82-92 are copied from the pending claims of Application Serial No.

09/824,447, as follows:

Serial No. 09/730,380

Response Under 37 C.F.R. §1.111

Docket No. 5432/01004

Page 9

New Claim	Corresponding Claim in Application Serial No. 09/844,447
82	9
83	10
84	11
85	12
86	13
87	14
88	15
89	16
90	17
91	18
92	19

Support for claims 82-92 is found in the application as filed, including at page 4, lines 20-27 and page 7, line 24 to page 8, line 16.

The Examiner is requested to consider whether an interference should be declared between at least claims 16-19 and 62-92 of this application and claims 1-19 of U.S. Patent Application Serial No. 09/824,447.

Serial No. 09/730,380 Response Under 37 C.F.R. §1.111

Docket No. 5432/0I004 Page 10

Favorable action is earnestly solicited.

December 5, 2002

Respectfully submitted,

on C. Todaro

Aftorney for Applicants

Reg. No. 36,036

Darby & Darby P.C. 805 Third Avenue New York, NY 10022 (212) 527-7700

M:\5432\01004\LRD2072.DOC

Serial No. 09/730,380 Response Under 37 C.F.R. §1.111 Docket No. 5432/0I004 Page 11